Source comparison
Stacking MOTS-C SS-31: Mitochondrial Stack Comparison
Primary Target AMPK activation, nuclear gene regulation Cardiolipin binding, membrane stabilization Dual-pathway mitochondrial protection and biogenesis Complementary. No receptor competition Metabolic Effect Increased insulin sensitivity, fatty acid oxidation
This comparison does not assign a generated winner or score.
- Primary Target
- AMPK activation, nuclear gene regulation
- Cardiolipin binding, membrane stabilization
- Dual-pathway mitochondrial protection and biogenesis
- Complementary. No receptor competition
- Metabolic Effect
- Increased insulin sensitivity, fatty acid oxidation, thermogenesis
- No direct metabolic signaling. Preserves existing ATP synthesis efficiency
- Enhanced substrate utilization with protected energy output
- Additive metabolic benefit without redundancy
- Structural Impact
- Upregulates PGC-1α. Increases mitochondrial biogenesis over 6–8 weeks
- Prevents cardiolipin oxidation. Maintains membrane integrity
- More mitochondria that remain functional under stress
- Addresses quantity and quality simultaneously
- Dosing Window (Research)
- 5–15 mg/kg 3–5× weekly (animal models)
- 3–5 mg/kg IV or 40 mg daily SC (clinical trials)
- Staggered timing may optimize acute effects
- Separation of 30–60 minutes recommended
- Primary Research Application
- Metabolic disease models, aging, insulin resistance
- Ischemia-reperfusion, heart failure, mitochondrial myopathy
- Combined metabolic and oxidative stress models
- Ideal for studies requiring both endpoints
- Oxidative Stress Reduction
- Indirect. AMPK activation reduces ROS production over time
- Direct. Prevents electron transport chain disruption
- Immediate membrane protection plus long-term ROS reduction
- SS-31 protects during MOTS-C adaptation period